Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood cancer drug bomedemstat tested for Long-Term safety

NCT ID NCT06351631

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows about 400 people with certain blood cancers (like essential thrombocythemia and myelofibrosis) who are already taking bomedemstat and benefiting from it. The goal is to collect more information on the drug's long-term safety and how well it controls the disease over time. Participants will continue taking bomedemstat capsules and be monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
bomedemstat (oral capsules)
What this could lead to
If successful, this study could confirm that bomedemstat is safe and effective for long-term use in controlling certain blood cancers.
What could go wrong
This is an extension study with no hypothesis testing, so it won't prove the drug works. Side effects are possible, and results may not apply to new patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera essential thrombocythemia myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS POLYCYTHEMIA VERA POST POLYCYTHEMIA VERA MYELOFIBROSIS POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS PRIMARY MYELOFIBROSIS THROMBOCYTHEMIA ESSENTIAL

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aotearoa Clinical Trials ( Site 1400)

    ACTIVE_NOT_RECRUITING

    Auckland, 2025, New Zealand

  • Azienda Ospedaliera Universitaria Careggi ( Site 2700)

    RECRUITING

    Florence, Tuscany, 50134, Italy

  • Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo ( Site 2703)

    RECRUITING

    Alessandria, 15121, Italy

  • Boston Pilgrim Hospital ( Site 3403)

    RECRUITING

    Boston, Lincolnshire, PE21 9QS, United Kingdom

  • DUHS Duke Blood Cancer Center ( Site 6005)

    RECRUITING

    Durham, North Carolina, 27705, United States

  • Gold Coast University Hospital-Cancer and Blood Disorders Clinical Trial Team ( Site 1002)

    RECRUITING

    Southport, Queensland, 4215, Australia

  • Guy's & St Thomas' NHS Foundation Trust ( Site 3401)

    RECRUITING

    London, London, City of, SE1 9RT, United Kingdom

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola ( Site 2702)

    RECRUITING

    Bologna, 40138, Italy

  • Imperial College Healthcare NHS Trust - Hammersmith Hospital ( Site 3402)

    RECRUITING

    London, Hammersmith and Fulham, W12 0HS, United Kingdom

  • Monash Health ( Site 1004)

    RECRUITING

    Clayton, Victoria, 3168, Australia

  • North Shore Hospital-Department of Haematology ( Site 1401)

    ACTIVE_NOT_RECRUITING

    Auckland, 0622, New Zealand

  • Ospedale di Circolo e Fondazione Macchi Varese ( Site 2701)

    RECRUITING

    Varese, 21100, Italy

  • Queen Mary Hospital ( Site 1601)

    ACTIVE_NOT_RECRUITING

    Hksar, Hong Kong

  • Royal Adelaide Hospital-Haematology Clinical Trials Unit ( Site 1000)

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • Royal North Shore Hospital ( Site 1001)

    RECRUITING

    St Leonards, New South Wales, 2065, Australia

  • Royal Prince Alfred Hospital ( Site 1003)

    RECRUITING

    Camperdown, New South Wales, 2050, Australia

  • Sunshine Coast Hematology and Oncology Clinic ( Site 1006)

    RECRUITING

    Buderim, Queensland, 4556, Australia

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 6007)

    RECRUITING

    Columbus, Ohio, 43210, United States

  • UPMC Hillman Cancer Center ( Site 6004)

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • University College London Hospital ( Site 3400)

    RECRUITING

    London, London, City of, NW1 2PG, United Kingdom

  • University of Michigan ( Site 6000)

    RECRUITING

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.